
ACEé»å®³è¬ãšARBã®äœµçšã¯ããã®ãïŒ
ããæ¥è³ç¥çµå€ç§ã®åŠæ¹ã§
Rp1ããã«ãµã«ã¿ã³é 80mgãïŒé
ããããïŒæ¥ïŒåãæé£åŸ
Rp2ãã·ã«ããžãã³é 10mgãïŒé
ããããïŒæ¥ïŒåãæé£åŸ
ãã®åŠæ¹ã«ããè¡å§ãäžãããªããšæè¡ãã§ããªãããšããçç±ã§ã
Rp3ãã€ããããªã«é 5mgãïŒé
ããããïŒæ¥ïŒåãæé£åŸ
ã远å ãšãªã£ãŠããã
ã²ãšæåã¯ããŸã«èŠãããåŠæ¹ã ã£ãããä¹
ãã¶ãã«ãã®åŠæ¹ãã¿ãŠããããã£ãŠè¯ãã£ããã ã£ãïŒãã£ãŠæããŸããã
ããããä»ã«ãã«ã«ã·ãŠã æ®æè¬ïŒCCBïŒã®å¢éãŸãã¯å€æŽãARBå¢éãå©çšè¬è¿œå ãÎ±é®æè¬ïŒÎ±ãŒïœïŒè¿œå ãÎ²é®æè¬ïŒÎ²ãŒïœïŒè¿œå ãªã©ææ®µã¯ããã€ãæ®ãããŠããæ®µéã§ãACEé»å®³è¬äœµçšã«èžã¿åã£ãã®ã¯ãªããªã®ãïŒ
ACEé»å®³è¬ãšARBã®äœµçšã¯ããã®ãïŒ
ããŸãçŸåšã®ãã«ãµã«ã¿ã³é ã®æ·»ä»ææžäžã§ã¯ã
ãäœµçšæ³šæãã¢ã³ãžãªãã³ã·ã³å€æé µçŽ é»å®³å€
ïŒèšåºçç¶ã»æªçœ®æ¹æ³ïŒ
ãè æ©èœé害ãé«ã«ãªãŠã è¡çåã³äœè¡å§ãèµ·ãããããããããããè æ©èœãè¡æž ã«ãªãŠã å€åã³è¡å§ãååã«èгå¯ããããš
ïŒæ©åºã»å±éºå åïŒ
䜵çšã«ããã¬ãã³ãŒã¢ã³ãžãªãã³ã·ã³ç³»é»å®³äœçšãå¢åŒ·ãããå¯èœæ§ãããã
ãšèšèŒãããŠããã䜵çšããå Žåã«ã¯æ³šæãå¿ èŠãªè¬å€ãšãªã£ãŠããŸãã
ã§ã¯ããã®æ·»ä»ææžã«ãã®æèšã远å ãããã®ã¯ãã€ãªã®ãïŒ
å¹³æ26幎6æ3æ¥ä»åçåŽåçå»è¬é£åå±å®å
šå¯Ÿç課é·éç¥ã«ããæ³šæäºé
ãïŒïŒïŒïŒå¹ŽïŒæããã«è¿œèšãããŠããŸãã
ã©ãããçµç·¯ã§âäœµçšæ³šæâã«æèšã远èšãããã®ãïŒ
Googleãã©ãŠã¶ã§ãACEé»å®³è¬ãARBã䜵çšãã®ããŒã¯ãŒããå ¥ããŠæ€çŽ¢ããŠã¿ããšä»¥äžã®ç»åã®ãããªãã®ããããããŒãžã«è¡šç€ºãããã
ããã ãèŠãŠãã䜵çšã¯ããŸããããªãããããªããïŒãšããæããããŸãã
ããŒãžã®ãããã«åºãŠããæ¥æ¬å»äºæ°å ±ç€Ÿã®2014幎10æã®èšäºãã¿ãŠã¿ããš
çè«äžã¯ïŒACEé»å®³è¬ãšARBã䜵çšããŠRAç³»ããããã¯ããããšã§ïŒåç¬çæ³ã«æ¯ã¹ãŠé«ã广ãåŸããããšèãããããïŒå¿è¡ç®¡ã€ãã³ãã®é«ãªã¹ã¯ç³å°¿ç æ£è ã察象ãšããONTARGET詊éšã§ã¯äœµçšçæ³ã«ããäžä¹ã广ã¯èªããããïŒéç¯€ãªæå®³äºè±¡ãå€ãã£ããšãããŠããïŒæç®1ïŒã
æç®ïŒïŒMann JFïŒ et al:Lancet. 2008;372(9638):547-53.ãPMIDïŒ 18707986
VA NEPHRON-D詊éšã§ãïŒäž¡è ã®äœµçšã¯é«ã«ãªãŠã è¡çãæ¥æ§è äžå šã®ãªã¹ã¯äžæããããããããïŒè©Šéšã¯äºå®ããå€§å¹ ã«ççž®ããæã¡åãããããããŸã§ã®è§£æã«ãããŠãïŒäž¡è ã®äœµçšã«ãªã¹ã¯ãäžåãèšåºçåªäœæ§ã¯èªããããªãã£ãïŒæç®2ïŒã
æç®ïŒïŒFried LFïŒ et al:N Engl J Med. 2013;369(20): 1892-903.ãPMID: 24206457
ãšèšèŒãããŠããã
ãŸãã2015幎12æã®DI onlineã«æ²èŒãããéå³¶å çã®ãçäŸããåŠã¶ãè¬å€åž«ã®ããã®EBMãã®é£èŒèšäºã§ãããããšããããããŠããã2013幎ã®ã¡ã¿è§£æã®è«æã®èª¬æãè¡ããªãããæçµçãªçµè«ãšããŠ
ãäž¡å€ã®äœµçšçæ³ã®æå¹æ§ã¯æç¢ºã«ç€ºãããŠããããè€æ°ã®ç ç©¶ã§æå®³æ§ãå ±åãããŠããããšãããçŸæç¹ã§ã¯ä»å€ãžã®ä»£æ¿ããæ³å®ã§ããªãã±ãŒã¹ãé€ããäœµçšæ³šæã§ãã£ãŠãççŸ©ç §äŒãè¡ã£ãæ¹ããããšèããŠãããã
ãšç· ãããã£ãŠããŸãã
ã¡ã¿è§£æïŒMakani H, Bangalore S, Desouza KA.et.al.
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.ãïŒãããããã®ã¡ã¿è§£æãåºã«ããŠæ·»ä»ææžã®æ¹èšã«è³ã£ãŠãããšæãããïŒ
ãããŸã§ã®æµããã¿ããš2015å¹Žã®æ®µéãŸã§ã¯ãã¡ãªããããããã¡ãªãããäžåãããšããããããã»ãã«ææ®µããªããšãã«èããŸããããšããããšã«ãªããšæããŸãã
ïŒïŒïŒïŒå¹Žä»¥éã«äœãç¶æ³ãå€ãã£ãã®ãïŒ
ãããã§ã¯ãæ·»ä»ææžæ¹èšåŸã«æ°ããªæç®å ±åãåºãŠç¶æ³ãå€ãã£ãã®ãïŒ
ãDI Onlineã®é£èŒã®ãšããã§ãéå³¶å
çãæ€çŽ¢ã¯ãŒããšããŠçšããŠãã
ãClinical Queriesãæ€çŽ¢ã¯ãŒããrenin-angiotensin system Combinationããcategoryãtherapyããscopeãnarrowãã§2016幎以éã®è«æãPubmedã§æ€çŽ¢ããŠã¿ãã
çµæãïŒïŒä»¶ãããããã²ãšã€ãã€ã¢ãã¹ãã©ã¯ããã¿ãŠãããšãACEé»å®³è¬ãšARBã®äœµçšã§ãããããã®ã¯ïŒæç®ã§ããã
Saglimbene V, et al. J Am Soc Nephrol 2018 - Clinical Trial. PMID 30420421
ããžã¢ããå šæãªã³ã¯ã«ãããŸãããïŒPubmedããïŒ
äžç床ïœé床ã®ã¢ã«ããã³å°¿ãæããç³å°¿ç æ£è ïŒ1243äŸïŒã察象ãšããŠ
ãã»ACEé»å®³è¬åç¬ïŒ413äŸïŒ
ãã»ARBåç¬ïŒ414äŸïŒ
ãã»ACEé»å®³è¬ïŒARBïŒ416äŸïŒ
PROBEæ³ã§å®æœã
æå¹æ§ïŒå¿è¡ç®¡æ»ãå¿çæ¢å¡ãè³åäžãããã³å¿è¡ç®¡æ§åå ã«ããå ¥é¢ã®åã ã®ãšã³ããã€ã³ãã®ãªã¹ã¯ãESRDç§»è¡ãã¯ã¬ã¢ããã³åå ãâ»ææå·®ãªã
å®å šæ§ïŒéç¯€ãªæå®³äºè±¡ãäœè¡å§ãé«ã«ãªãŠã è¡çãâ»ææå·®ãªã
ä»ãŸã§ã¯ãããããªæå¹æ§ã¯èªããããããªã¹ã¯ãå¢å ãšããæç®ãå€ãã£ãã§ãããããã¯æå¹æ§ãå®å šæ§ãäž¡æ¹ææå·®ããªãã£ããšãããã®ããšæããŸãã
ãä»ã®æ€çŽ¢æ¡ä»¶ã§ã¯éææ£è ãç³å°¿ç æ£è ã察象ãšãããã®ãããã€ããããããŠããŸããããæ°ããªç¥èŠãå«ãã ãã®ã¯ãªãããã«æããŸããã
Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review
ããããLi SM, et al. Atherosclerosis 2018. PMID 29258005
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
ããããCatalá-López F, et al. PLoS Med 2016 - Review. PMID 26954482 Free PMC article.
ãããã«
ããããã®èª¿ã¹ãæ å ±ãåºã«ãæ·»ä»ææžå€æŽãšãªã£ãçµç·¯ãå ãšãªã£ãŠããæç®æ å ±ãªã©ãèšèŒããŠãå»åž«ãžããã¬ãŒã·ã³ã°ã¬ããŒãããéä»ããŸããã
ãã®åŸãåœè©²æ£è ãããæ¥å±ãããŸãããã
Rp.4ãããœããããŒã«é 2.5mgãïŒé
ãããããããããïŒæ¥ïŒåæé£åŸ
ã远å ãšãªã£ãŠããŸãããæ¥å±æã§ãåçž®æè¡å§ã¯150mmHgãããŸã è¡å§ãäžããå¿ èŠã¯ãã£ããã远å ãšãªã£ããšããäºã§ãã
å®å
šæ§ã«é¢ãããšãã
äœè¡å§ãé«Kã®ã¢ãã¿ãªã³ã°ã§
ãè¡å§äœäžããµãã€ãã«ã€ããŠç¢ºèª
è
æ©èœé害ã®ã¢ãã¿ãªã³ã°ã§
ãå°¿éäœäžãããã¿ã«ã€ããŠç¢ºèª
ããåé¡ãªããšã®è¿çã¯æ£è
ããããããããŸããã
è¡å§ãäžãããšããç®çã®ã¿ã§ã®äœµçšãšèãããããããä»åŸãç¶ç¶ããŠå¯äœçšã¢ãã¿ãªã³ã°ãç¶ããŠãããããªãç¶æ
ãšãªã£ãŠããŸãã



